There are a lot of new and exciting agents that are being explored for metastatic HER2-positive disease, explained Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute.
There are a lot of new and exciting agents that are being explored for metastatic HER2-positive disease, explained Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute.
Transcript
What’s the current standard of care for HER2-positive breast cancer?
In the metastatic setting, generally, we start out using a taxane with trastuzumab and pertuzumab, and then upon progression, we go on to trastuzumab DM1, and then thereafter, it’s really chemotherapy combined with anti-HER2 therapy. In patients who have hormone-receptor-positive HER2-positive disease, we sometimes will integrate endocrine therapy with dual anti-HER2 therapy along the course of their therapy.
What novel approaches are being taken for the treatment of HER2-positive breast cancer?
There are a lot of new and exciting agents that are being explored for metastatic HER2-positive disease. I think one particular class that’s exciting are the antibody-drug conjugates. So, there’s one agent, the DS-8201a agent. So, it’s an antibody-drug conjugate targeting HER2, and it delivers a topoisomerase 1 payload. They’ve demonstrated about a 60% objective response in metastatic HER2-positive breast cancer, and they uniquely even have activity in HER2-low-positive tumors, with about a 30% response.
Outside of that agent, which is made by Daiichi, there’s several other antibody-drug conjugates. So, here we saw results from a trial looking at SYD985, which is an antibody-drug conjugate that delivers a DNA alkylator payload, and they demonstrated a little over a 30% objective response in pretreated HER2-positive disease. Those 2 agents, along with several other antibody-drug conjugates that are coming along, including now even bispecific antibody-drug conjugates, I think, may really be a great opportunity for a lot of our patients, because you could imagine these agents may either be better than T-DM1 and replace it in the second line setting, or could work in T-DM refractory patients, and so really move into the third line setting.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More